

## Global Glycopeptide Antibiotics Market Size, Share, And Growth Analysis For 2024-2033

The Business Research Company's Glycopeptide Antibiotics Global Market Report 2024– Market Size, Trends, And Global Forecast 2024-2033

LANDON, GREATER LANDON, UNITED KINGDOM, September 27, 2024 /EINPresswire.com/ -- The glycopeptide antibiotics market has experienced



robust growth in recent years, expanding from \$3.31 billion in 2023 to \$3.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases.



It will grow to \$5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%.

The Business Research
Company

What Is The Estimated Market Size Of The Global Glycopeptide Antibiotics Market And Its Annual Growth Rate?

The glycopeptide antibiotics market is projected to continue its strong growth, reaching \$5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to

emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, R&D investments and innovations, expansion of healthcare infrastructure.

Explore Comprehensive Insights Into The Global Glycopeptide Antibiotics Market With A Detailed Sample Report:

https://www.thebusinessresearchcompany.com/sample\_request?id=9444&type=smp

Growth Driver Of The Glycopeptide Antibiotics Market

The rising number of cancer and infectious disease cases is expected to propel the growth of the glycopeptide antibiotics market going forward. Cancer refers to a disease that occurs when certain body cells multiply beyond their limits and spread to other body regions, whereas,

infectious diseases are disorders produced by organisms such as bacteria, viruses, fungus, or parasites. The glycopeptide antibiotics are used to treat a variety of infectious disorders caused by methicillin-resistant staphylococcus aureus, streptococcus, or enterococcus bacteria that are resistant to beta-lactams and other antibiotics. In cancer patients, glycopeptide antibiotics are used to boost radiotherapy's antitumor effects by eliminating not only the targeted cancer cells but also distant cancer cells farther in the body.

Explore The Report Store To Make A Direct Purchase Of The Report: <a href="https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report">https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report</a>

Which Market Players Are Driving The Glycopeptide Antibiotics Market Growth?

Key players in the market include ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Melinta Therapeutics Inc., Cumberland Pharmaceuticals Inc., Theravance Biopharma Inc., Janssen Global, Bristol-Myers Squibb Company, GSK Plc., Allergan Plc., Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, Targanta Therapeutics, GlaxoSmithKline PLC, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

What Are The Emerging Trends Shaping The Glycopeptide Antibiotics Market Size? Major companies operating in the glycopeptide antibiotics market are adopting a strategic partnership approach, aiming to bring life-saving revolutionary antibiotics to the Middle East. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success.

How Is The Global Glycopeptide Antibiotics Market Segmented?

- 1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
- 2) By Route of Administration: Oral, Parenteral, Other Routes
- 3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
- 4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Geographical Insights: North America Leading The Glycopeptide Antibiotics Market North America was the largest region in the market in 2023. The regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Glycopeptide Antibiotics Market Definition

Glycopeptide antibiotics are a group of antibiotics having structures that either comprise a glycosylated cyclic or polycyclic non-ribosomal peptide, used to inhibit bacterial cell wall formation. They were first discovered from plant and soil bacteria.

The main drugs of glycopeptide antibiotics are vancomycin, dalbavancin, oritavancin, and others. Vancomycin belongs to a family of drugs known as glycopeptide antibiotics that eliminates microorganisms in the intestines and is used to treat colitis, which can develop after antibiotic therapy. These are administered through oral, parenteral, and other routes for the treatment of skin and structure infection, meningitis, clostridioides difficile infection, enterocolitis, and other indications by hospitals, specialty clinics, home care, and other end-users.

<u>Glycopeptide Antibiotics Global Market Report 2024</u> from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- •Macroeconomic factors affecting the market in the short and long run
- •Analysis of the macro and micro economic factors that have affected the market in the past five years
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

An overview of the global glycopeptide antibiotics market report covering trends, opportunities, strategies, and more

The Glycopeptide Antibiotics Global Market Report 2024 by <u>The Business Research Company</u> is the most comprehensive report that provides insights on glycopeptide antibiotics market size, glycopeptide antibiotics market drivers and trends and glycopeptide antibiotics market growth across geographies. This report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Nutritional Feed Additives Global Market Report 2024 <a href="https://www.thebusinessresearchcompany.com/report/nutritional-feed-additives-global-market-report">https://www.thebusinessresearchcompany.com/report/nutritional-feed-additives-global-market-report</a>

Pharmacies and Drug Stores Global Market Report 2024 <a href="https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report">https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report</a>

Anticoagulants Global Market Report 2024

## https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

What Does The Business Research Company Do?

The Business Research Company publishes over 15,000 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package, and much more.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook Χ LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/746656607

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.